Tatva Chintan Pharma Chem Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹4.0K Cr
Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and IC engines. Tatva Chintan expects improved business prospects over the coming quarters with faint signs of market recovery and stable raw material prices.
From Tatva Chintan Pharma Chem Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,616
Market Cap
₹4.0K Cr
P/E Ratio
76.8
How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?
Compare Tatva Chintan Pharma Chem Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr.
Full financials →📊 Revenue & Sales Performance
📈 Profitability & Margins
- →Tatva Chintan expects improved business prospects over the coming quarters with faint signs of market recovery and stable raw material prices.
- →Commercialization of new products, especially in pharma, agro intermediates, semiconductor, and energy storage segments, is expected to drive future growth, starting late 2025 and into 2026.
- →PASC segment aims for revenue of INR 80-100 crore next year with healthy EBITDA margins as volume increases.
- →The electrolyte salts and hybrid car battery segments are gaining momentum, with pilot scale-up expected from April 2025.
- →Plant utilization is expected to reach near full capacity by June-July 2025, with process optimization efforts to enhance productivity.
- →Revenue potential could surpass INR 900 crores with existing and upcoming capacities by 2026.
- →Despite short-term EBITDA margin pressure due to new product mix, the overall gross margin is expected to stabilize around 45%.
- →Semiconductor-grade product development targeting ultra-high purity levels is anticipated to open a large market opportunity within 4-6 months.
🏗️ Capital Expenditure Plans
- →A new plant is under construction on the existing Dahej site for agro intermediates, expected to be ready for production in Q4 of FY 2026.
- →A new plant is expected to become operational by January 2026 to support future growth and handle full occupancy as the existing plant reaches capacity by June-July 2025.
- →Expansion related to the distillation plant started in January to ease production capacities for major products.
- →Commercialization of a pharma intermediate product is anticipated by end of 2025 or early 2026 with a fourth product under approval for commercialization by end of next calendar year.
- →Equipment capable of handling 1000kg for Monoglyme is expected by end of FY 2025, with installation and commercialization by June 2025.
- →Focus on R&D for semiconductor and electronics industry products as future growth engines over the next three years.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned new fundraising through debt or equity in the provided transcript of the Tatva Chintan Pharma Chem Limited earnings call dated January 28, 2025.
- →The discussion primarily focuses on business developments, R&D progress, market demand, and operational updates.
- →No questions or answers address fundraising activities or capital raising plans.
- →The company appears focused on commercializing new products and optimizing existing operations rather than seeking external capital at this time.
📋 Order Book & Pipeline
- →The transcript does not explicitly mention the exact current or expected order book size in financial terms.
- →However, several indications of growing order flow and upcoming commercializations are noted:
- → - Two large agro intermediates under approval are expected to get final clearance soon, with commercialization starting immediately.
- → - Four agro intermediates under approval basis are expected to see commercialization during the current year.
- → - The Phase Transfer Catalyst segment has onboarded two new multinational customers, with commercial business started and volumes expected to ramp up over coming quarters.
- → - The electrolyte salts segment is gaining momentum, with pilot-scale scale-up planned by April following positive lab results.
- → - Structure-Directing Agent (SDA) customers are showing early signs of demand recovery, with two large customers ready for commercial supply from April 2025.
- →Logistics and warehousing arrangements are ongoing to ensure smooth and continuous supply for global customers.
Key Metrics
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q3 FY25 results?
Encouraging signs of market recovery with early demand uptick in SDA segment, especially due to hybrid and IC engines. Tatva Chintan expects improved business prospects over the coming quarters with faint signs of market recovery and stable raw material prices.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
A new plant is under construction on the existing Dahej site for agro intermediates, expected to be ready for production in Q4 of FY 2026.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.